Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Immunome, Inc.

In a report released today, Cory Kasimov from Evercore ISI maintained a Buy rating on Immunome, with a price target of $40.00. Kasimov covers the H...

Evercore ISI Remains a Buy on Immunome (IMNM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fennec Pharmaceuticals (FENC) and Immunome (IMNM) wi...

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM), Neurogene (NGNE) and Seer (SEER) wi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMNM	$26.76	-1.47%	562.13K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMNM	$26.76	-1.5%	562.13K
3
4
5
6

IMNM

Get Immunome, Inc. Data in Excel

Get Immunome, Inc. Data in Excel